A just-published article in the Journal of Clinical & Aesthetic Dermatology confirms that rosacea sufferers who are using Zilxi to treat their papules and pustules can safely continue treatment for at least a year. Further, users can expect the benefit in terms of lesion reduction and satisfaction to increase as the year progresses.
This is good news for rosacea sufferers as very few Zilxi User Reviews are available online. Please do tell us if you get to try Zilxi yourself.
CONCLUSION: Overall, FMX103 1.5% appeared to be safe, well tolerated, and effective for the long-term treatment of papulopustular rosacea. The long-term safety profile after 52 weeks of daily application was similar to that seen after the 12 weeks of use in the double-blind Phase 3 studies.
During the additional 40 weeks of treatment, continuous improvement in lesion reduction and IGA treatment success was demonstrated by the subjects treated with FMX103 1.5%.
Taken together with data from the double-blind studies, which demonstrated significant improvements as compared with vehicle foam, the current results provide further evidence supporting the potential of FMX103 1.5% to be a suitable option for the treatment for moderate-to-severe papulopustular rosacea..
This study was sponsored by Foamix Pharmaceuticals Ltd., a wholly owned subsidiary of VYNE Therapeutics Inc.
What is Zilxi?
Zilxi is a 1.5% Topical Minocycline Foam, approved by the FDA for the treatment of the papules and pustules of rosacea. Zilxi is available on prescription as a 30g canister.
Is using topical Zilxi like oral minocycline?
This question was answered by the study, as researchers were able to show that the frequency of adverse events for topical minocycline is lower than that for oral minocycline.
An important outcome was that the most concerning events that are typically associated with oral minocycline were not observed with extended use of FMX103 1.5%
Zilxi – a promising new treatment?
The paper does read a bit like a promotional effort (VYNE did pay for the research after all). The authors suggesting that Zilxi may constitute a promising new therapy for rosacea.
Together, the positive efficacy outcomes, favorable 52-week safety profile, and patient satisfaction with FMX103 1.5% may foster patients’ adherence to therapy. A positive effect on treatment adherence would likely result in increased rates of treatment success among rosacea patients, suggesting that FMX103 1.5% topical minocycline foam could be a promising new therapy for the management of rosacea.
